Human papillomavirus infection in genital women in four regions of Senegal
El HadjiSeydou Mbaye*1,2,3, Tarik Gheit1, Ahmadou Dem3, Sandrine McKay-Chopin1, NdeyeCoumba Toure-Kane2, Souleymane Mboup2, Massimo Tommasino1, Bakary S.Sylla1, and CheikhSaadBouh Boye2
1International Agency for Research on Cancer (IARC/WHO), Lyon, France
2 Laboratory of Bacteriology and Virology, Aristide Le Dantec Hospital, Dakar, Senegal
3Cancer Institute, Aristide Le Dantec Hospital, Dakar, Senegal
Citation: Mbaye EH, Ahmadou Dem TG, McKay-Chopin S, Toure-Kane NC, Mboup (2019) Human papillomavirus infection in genital women in four regions of Senegal. SciTech Bio-Cancer Sciences 2019. Tokyo: Japan
Received: May 10, 2019 Accepted: May 13, 2019 Published: May 13, 2019
Cervical cancer is the most frequent cancer among women in Senegal. However, there are few data concerning the HPV types inducing neoplasia and cervical cancers and their prevalence, in the general population of Senegal
The aim of this study is to determine the prevalence of HPV infection in Senegalese women aged from 18 years and older.
MATERIALS AND METHODS:
A study was performed on 498 cervix samples collected from healthy women aged 18 and older in Dakar. 438 other samples were collected from three other regions, Thiès, Saint Louis and Louga. The samples were screened for 21 HPV genotypes using an HPV type-specific E7 PCR bead-based multiplex genotyping assay (TS-MPG) which is a laboratory-developed method for the detection of HPV.
The prevalence for pHR/HR-HPV in the region of Dakar was 20.68%. HPV 52 (3.21%) was the most prevalent HPV type, followed by HPV 16 (3.01%) and HPV 31 (3.01%). In the regions of Thiès, Louga and Saint Louis, the prevalence for pHR/HR-HPV was 29.19%, 23.15% and 20%, respectively
The study revealed the specificity of the HR-HPV prevalence in Dakar and other regions of Senegal. The patterns differs from the one observed in the other regions of the world and rise the issue of the development of vaccination program in the country. Such a program should take into account the real HPV prevalence for an effective protection of HPV-associated diseases.